Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 10/20 | 0.46 |
| ▸ | DRD2 | P14416 | 8/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | DRD5 | P21918 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3854368 | 0.90 | AR (0.42) | CCR1DRD2AR | |
| SCHEMBL3853342 | 0.85 | CCR1 (0.48) | CCR1AR | |
| SCHEMBL3854549 | 0.84 | OPRM1 (0.48) | CCR1DRD2ARHTR1ADRD1 | |
| SCHEMBL3860349 | 0.84 | DRD2 (0.55) | DRD2HTR1ADRD1DRD5SLC6A2 | |
| SCHEMBL5503101 | 0.82 | CCR1 (0.46) | CCR1AR | |
| SCHEMBL3859083 | 0.82 | CCR1 (0.44) | CCR1 | |
| SCHEMBL3850839 | 0.82 | CCR1 (0.42) | CCR1 | |
| SCHEMBL4823323 | 0.81 | TRPV4 (0.47) | AR | |
| SCHEMBL3857869 | 0.81 | DRD2 (0.51) | DRD2HTR1ADRD1DRD5SLC6A2 | |
| SCHEMBL3851778 | 0.78 | DRD2 (0.52) | CCR1DRD2HTR1ADRD1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270467-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2007-11-22 | — | — | US | claimed |
| EP-1765779-A1 | NEW SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2007-03-28 | — | — | EP | claimed |
| WO-2005121092-A1 | NEW SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2005-12-22 | — | — | WO | claimed |
| US-7579474-B2 | Substituted piperidines as modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH AB, SVERIGE (DK) | 2009-08-25 | — | — | US | disclosed |
| US-20070270467-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2007-11-22 | — | — | US | disclosed |
| EP-1765779-A1 | NEW SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005121092-A1 | NEW SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270467-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | DRD2, PRLHR, DRD3 | CCR1 2632/4885DRD2 1/4885AR 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.